Recent Report on Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016
Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Refractory Acute Myeloid Leukemia (Oncology) pipeline landscape.
The acute myeloid leukemia cells which resist treatment are referred to as refractory acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfort in bones or joints such as knees, hips or shoulders. Predisposing factors include age, history of other blood cancers or disorders, genetic disorder and past chemotherapy or radiation treatments. Treatment options include drugs not already used during past treatment and conditioning therapy followed by transplantation.
To access full report with TOC, please visit Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016
Report Highlights
This report provides comprehensive information on the therapeutics under development for Refractory Acute Myeloid Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Refractory Acute Myeloid Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Refractory Acute Myeloid Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 34, 39, 1, 3, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 6 and 1 molecules, respectively.Refractory Acute Myeloid Leukemia.
Refractory Acute Myeloid Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Refractory Acute Myeloid Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Refractory Acute Myeloid Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology)
- The pipeline guide reviews pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Refractory Acute Myeloid Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Refractory Acute Myeloid Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Refractory Acute Myeloid Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Refractory Acute Myeloid Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG AbbVie Inc Actinium Pharmaceuticals Inc ADC Therapeutics Sarl Aeglea BioTherapeutics Inc Agios Pharmaceuticals Inc Aileron Therapeutics Inc Amgen Inc Arog Pharmaceuticals Inc Array BioPharma Inc Astellas Pharma Inc AstraZeneca Plc AVEO Pharmaceuticals Inc Bellicum Pharmaceuticals Inc Bio-Cancer Treatment International Ltd BioLineRx Ltd BioSight Ltd Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Calithera Biosciences Inc Celgene Corp Cornerstone Pharmaceuticals Inc CSPC Pharmaceutical Group Limited CTI BioPharma Corp Daiichi Sankyo Company Ltd Eisai Co Ltd Eli Lilly and Company EpiZyme Inc Exelixis Inc F. Hoffmann-La Roche Ltd Fate Therapeutics Inc FLX Bio, Inc. FORMA Therapeutics Inc Fujifilm Corp GlaxoSmithKline Plc GlycoMimetics Inc Igenica Biotherapeutics Inc Incyte Corp Io Therapeutics Inc JW Pharmaceutical Corp Karyopharm Therapeutics Inc Kyowa Hakko Kirin Co Ltd MacroGenics Inc Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc NantKwest Inc Novartis AG Oxford BioTherapeutics Ltd Pfizer Inc Pharma Mar SA Polaris Pharmaceuticals Inc Seattle Genetics Inc Sunesis Pharmaceuticals Inc TaiGen Biotechnology Co Ltd Tolero Pharmaceuticals Inc Tragara Pharmaceuticals Inc VioQuest Pharmaceuticals Inc ZIOPHARM Oncology Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 19:40
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home